Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer
Background We report the outcomes of cisplatin‐ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel. Materials and Methods We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin a...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2023-09, Vol.45 (9), p.2207-2216 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2216 |
|---|---|
| container_issue | 9 |
| container_start_page | 2207 |
| container_title | Head & neck |
| container_volume | 45 |
| creator | Han, James Zakeri, Kaveh Raab, Gabriel Hesse, Jennifer Shamseddine, Achraf Chen, Linda Yu, Yao Kang, Jung Julie McBride, Sean M. Riaz, Nadeem Tsai, C. Jillian Gelblum, Daphna Sherman, Eric J. Wong, Richard J. Michel, Loren Lee, Nancy Y. |
| description | Background
We report the outcomes of cisplatin‐ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel.
Materials and Methods
We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods.
Results
Sixty‐five patients were identified with median age of 71 years (range 44–85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m2, respectively. At a median follow‐up of 29 (range 5–91) months, the 2‐year rates of LRR, DM, PFS, and OS were 8.8%, 9.4%, 72.2%, and 88.7%, respectively. In total, there were 5 LRR, 7 DM, and 12 deaths.
Conclusions
Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin‐ineligible HNSCC patients. |
| doi_str_mv | 10.1002/hed.27456 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2836878679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2847971503</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3886-c600dd71c6b5282948cfbc89d8cfff685adb89fc89b21e4a66bb0f87a9d0b6003</originalsourceid><addsrcrecordid>eNp1kc1OGzEURi1URCiw4AWQpW7axYBn7NieJQppg4TEBtaj6z_FwbEHzwyQt68hsKnU1b36dHx05Q-h85pc1oQ0V2trLhvB5vwAHdekFRWhTHx73xmtKBFshr4Pw4YQQjlrjtCMCkbbRvJjFBYp6ilnG0esIavUBxh9xBAN7kEHP8KbDdhY56Mf_YvFGYwvSIp4XNsM_Q67lHFIGkLYYTAvELU1eG3BfFii1U9FXcJ8ig4dhMGefc4T9Ph7-bBYVXf3f24X13eVplLySnNCjBG15mreyKZlUjulZWvKdI7LORglW1cS1dSWAedKEScFtIao8paeoJ97b5_T82SHsdv6QdsQINo0DV0jKZdCctEW9Mc_6CZNOZbrCsVEK-o5oYX6tad0TsOQrev67LeQd11NuvcKulJB91FBYS8-jZPalvSL_PrzAlztgVcf7O7_pm61vNkr_wIPBpFN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2847971503</pqid></control><display><type>article</type><title>Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Han, James ; Zakeri, Kaveh ; Raab, Gabriel ; Hesse, Jennifer ; Shamseddine, Achraf ; Chen, Linda ; Yu, Yao ; Kang, Jung Julie ; McBride, Sean M. ; Riaz, Nadeem ; Tsai, C. Jillian ; Gelblum, Daphna ; Sherman, Eric J. ; Wong, Richard J. ; Michel, Loren ; Lee, Nancy Y.</creator><creatorcontrib>Han, James ; Zakeri, Kaveh ; Raab, Gabriel ; Hesse, Jennifer ; Shamseddine, Achraf ; Chen, Linda ; Yu, Yao ; Kang, Jung Julie ; McBride, Sean M. ; Riaz, Nadeem ; Tsai, C. Jillian ; Gelblum, Daphna ; Sherman, Eric J. ; Wong, Richard J. ; Michel, Loren ; Lee, Nancy Y.</creatorcontrib><description>Background
We report the outcomes of cisplatin‐ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel.
Materials and Methods
We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods.
Results
Sixty‐five patients were identified with median age of 71 years (range 44–85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m2, respectively. At a median follow‐up of 29 (range 5–91) months, the 2‐year rates of LRR, DM, PFS, and OS were 8.8%, 9.4%, 72.2%, and 88.7%, respectively. In total, there were 5 LRR, 7 DM, and 12 deaths.
Conclusions
Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin‐ineligible HNSCC patients.</description><identifier>ISSN: 1043-3074</identifier><identifier>ISSN: 1097-0347</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.27456</identifier><identifier>PMID: 37439286</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carboplatin ; Carboplatin - therapeutic use ; Chemoradiotherapy ; Chemoradiotherapy - adverse effects ; Cisplatin ; Cisplatin - therapeutic use ; cisplatin ineligible ; concurrent carboplatin and paclitaxel ; Head & neck cancer ; Head and Neck Neoplasms - drug therapy ; Humans ; locally advanced head and neck cancer ; Metastases ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; older age and comorbidities ; Paclitaxel ; Radiation therapy ; Squamous Cell Carcinoma of Head and Neck - drug therapy ; Survival</subject><ispartof>Head & neck, 2023-09, Vol.45 (9), p.2207-2216</ispartof><rights>2023 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3886-c600dd71c6b5282948cfbc89d8cfff685adb89fc89b21e4a66bb0f87a9d0b6003</citedby><cites>FETCH-LOGICAL-c3886-c600dd71c6b5282948cfbc89d8cfff685adb89fc89b21e4a66bb0f87a9d0b6003</cites><orcidid>0000-0003-3921-480X ; 0000-0002-0417-3879 ; 0000-0003-0400-2655</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.27456$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.27456$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37439286$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Han, James</creatorcontrib><creatorcontrib>Zakeri, Kaveh</creatorcontrib><creatorcontrib>Raab, Gabriel</creatorcontrib><creatorcontrib>Hesse, Jennifer</creatorcontrib><creatorcontrib>Shamseddine, Achraf</creatorcontrib><creatorcontrib>Chen, Linda</creatorcontrib><creatorcontrib>Yu, Yao</creatorcontrib><creatorcontrib>Kang, Jung Julie</creatorcontrib><creatorcontrib>McBride, Sean M.</creatorcontrib><creatorcontrib>Riaz, Nadeem</creatorcontrib><creatorcontrib>Tsai, C. Jillian</creatorcontrib><creatorcontrib>Gelblum, Daphna</creatorcontrib><creatorcontrib>Sherman, Eric J.</creatorcontrib><creatorcontrib>Wong, Richard J.</creatorcontrib><creatorcontrib>Michel, Loren</creatorcontrib><creatorcontrib>Lee, Nancy Y.</creatorcontrib><title>Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
We report the outcomes of cisplatin‐ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel.
Materials and Methods
We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods.
Results
Sixty‐five patients were identified with median age of 71 years (range 44–85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m2, respectively. At a median follow‐up of 29 (range 5–91) months, the 2‐year rates of LRR, DM, PFS, and OS were 8.8%, 9.4%, 72.2%, and 88.7%, respectively. In total, there were 5 LRR, 7 DM, and 12 deaths.
Conclusions
Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin‐ineligible HNSCC patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carboplatin</subject><subject>Carboplatin - therapeutic use</subject><subject>Chemoradiotherapy</subject><subject>Chemoradiotherapy - adverse effects</subject><subject>Cisplatin</subject><subject>Cisplatin - therapeutic use</subject><subject>cisplatin ineligible</subject><subject>concurrent carboplatin and paclitaxel</subject><subject>Head & neck cancer</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Humans</subject><subject>locally advanced head and neck cancer</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>older age and comorbidities</subject><subject>Paclitaxel</subject><subject>Radiation therapy</subject><subject>Squamous Cell Carcinoma of Head and Neck - drug therapy</subject><subject>Survival</subject><issn>1043-3074</issn><issn>1097-0347</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1OGzEURi1URCiw4AWQpW7axYBn7NieJQppg4TEBtaj6z_FwbEHzwyQt68hsKnU1b36dHx05Q-h85pc1oQ0V2trLhvB5vwAHdekFRWhTHx73xmtKBFshr4Pw4YQQjlrjtCMCkbbRvJjFBYp6ilnG0esIavUBxh9xBAN7kEHP8KbDdhY56Mf_YvFGYwvSIp4XNsM_Q67lHFIGkLYYTAvELU1eG3BfFii1U9FXcJ8ig4dhMGefc4T9Ph7-bBYVXf3f24X13eVplLySnNCjBG15mreyKZlUjulZWvKdI7LORglW1cS1dSWAedKEScFtIao8paeoJ97b5_T82SHsdv6QdsQINo0DV0jKZdCctEW9Mc_6CZNOZbrCsVEK-o5oYX6tad0TsOQrev67LeQd11NuvcKulJB91FBYS8-jZPalvSL_PrzAlztgVcf7O7_pm61vNkr_wIPBpFN</recordid><startdate>202309</startdate><enddate>202309</enddate><creator>Han, James</creator><creator>Zakeri, Kaveh</creator><creator>Raab, Gabriel</creator><creator>Hesse, Jennifer</creator><creator>Shamseddine, Achraf</creator><creator>Chen, Linda</creator><creator>Yu, Yao</creator><creator>Kang, Jung Julie</creator><creator>McBride, Sean M.</creator><creator>Riaz, Nadeem</creator><creator>Tsai, C. Jillian</creator><creator>Gelblum, Daphna</creator><creator>Sherman, Eric J.</creator><creator>Wong, Richard J.</creator><creator>Michel, Loren</creator><creator>Lee, Nancy Y.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3921-480X</orcidid><orcidid>https://orcid.org/0000-0002-0417-3879</orcidid><orcidid>https://orcid.org/0000-0003-0400-2655</orcidid></search><sort><creationdate>202309</creationdate><title>Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer</title><author>Han, James ; Zakeri, Kaveh ; Raab, Gabriel ; Hesse, Jennifer ; Shamseddine, Achraf ; Chen, Linda ; Yu, Yao ; Kang, Jung Julie ; McBride, Sean M. ; Riaz, Nadeem ; Tsai, C. Jillian ; Gelblum, Daphna ; Sherman, Eric J. ; Wong, Richard J. ; Michel, Loren ; Lee, Nancy Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3886-c600dd71c6b5282948cfbc89d8cfff685adb89fc89b21e4a66bb0f87a9d0b6003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carboplatin</topic><topic>Carboplatin - therapeutic use</topic><topic>Chemoradiotherapy</topic><topic>Chemoradiotherapy - adverse effects</topic><topic>Cisplatin</topic><topic>Cisplatin - therapeutic use</topic><topic>cisplatin ineligible</topic><topic>concurrent carboplatin and paclitaxel</topic><topic>Head & neck cancer</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Humans</topic><topic>locally advanced head and neck cancer</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>older age and comorbidities</topic><topic>Paclitaxel</topic><topic>Radiation therapy</topic><topic>Squamous Cell Carcinoma of Head and Neck - drug therapy</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Han, James</creatorcontrib><creatorcontrib>Zakeri, Kaveh</creatorcontrib><creatorcontrib>Raab, Gabriel</creatorcontrib><creatorcontrib>Hesse, Jennifer</creatorcontrib><creatorcontrib>Shamseddine, Achraf</creatorcontrib><creatorcontrib>Chen, Linda</creatorcontrib><creatorcontrib>Yu, Yao</creatorcontrib><creatorcontrib>Kang, Jung Julie</creatorcontrib><creatorcontrib>McBride, Sean M.</creatorcontrib><creatorcontrib>Riaz, Nadeem</creatorcontrib><creatorcontrib>Tsai, C. Jillian</creatorcontrib><creatorcontrib>Gelblum, Daphna</creatorcontrib><creatorcontrib>Sherman, Eric J.</creatorcontrib><creatorcontrib>Wong, Richard J.</creatorcontrib><creatorcontrib>Michel, Loren</creatorcontrib><creatorcontrib>Lee, Nancy Y.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Han, James</au><au>Zakeri, Kaveh</au><au>Raab, Gabriel</au><au>Hesse, Jennifer</au><au>Shamseddine, Achraf</au><au>Chen, Linda</au><au>Yu, Yao</au><au>Kang, Jung Julie</au><au>McBride, Sean M.</au><au>Riaz, Nadeem</au><au>Tsai, C. Jillian</au><au>Gelblum, Daphna</au><au>Sherman, Eric J.</au><au>Wong, Richard J.</au><au>Michel, Loren</au><au>Lee, Nancy Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2023-09</date><risdate>2023</risdate><volume>45</volume><issue>9</issue><spage>2207</spage><epage>2216</epage><pages>2207-2216</pages><issn>1043-3074</issn><issn>1097-0347</issn><eissn>1097-0347</eissn><abstract>Background
We report the outcomes of cisplatin‐ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel.
Materials and Methods
We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods.
Results
Sixty‐five patients were identified with median age of 71 years (range 44–85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m2, respectively. At a median follow‐up of 29 (range 5–91) months, the 2‐year rates of LRR, DM, PFS, and OS were 8.8%, 9.4%, 72.2%, and 88.7%, respectively. In total, there were 5 LRR, 7 DM, and 12 deaths.
Conclusions
Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin‐ineligible HNSCC patients.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>37439286</pmid><doi>10.1002/hed.27456</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-3921-480X</orcidid><orcidid>https://orcid.org/0000-0002-0417-3879</orcidid><orcidid>https://orcid.org/0000-0003-0400-2655</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2023-09, Vol.45 (9), p.2207-2216 |
| issn | 1043-3074 1097-0347 1097-0347 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2836878679 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin Carboplatin - therapeutic use Chemoradiotherapy Chemoradiotherapy - adverse effects Cisplatin Cisplatin - therapeutic use cisplatin ineligible concurrent carboplatin and paclitaxel Head & neck cancer Head and Neck Neoplasms - drug therapy Humans locally advanced head and neck cancer Metastases Middle Aged Neoplasm Recurrence, Local - drug therapy older age and comorbidities Paclitaxel Radiation therapy Squamous Cell Carcinoma of Head and Neck - drug therapy Survival |
| title | Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A07%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Concurrent%20carboplatin%20and%20paclitaxel%20definitive%20radiation%20therapy%20for%20locally%20advanced%20head%20and%20neck%20cancer&rft.jtitle=Head%20&%20neck&rft.au=Han,%20James&rft.date=2023-09&rft.volume=45&rft.issue=9&rft.spage=2207&rft.epage=2216&rft.pages=2207-2216&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.27456&rft_dat=%3Cproquest_cross%3E2847971503%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2847971503&rft_id=info:pmid/37439286&rfr_iscdi=true |